CA2377373A1 - Nitric oxide donors for inducing neurogenesis - Google Patents

Nitric oxide donors for inducing neurogenesis Download PDF

Info

Publication number
CA2377373A1
CA2377373A1 CA002377373A CA2377373A CA2377373A1 CA 2377373 A1 CA2377373 A1 CA 2377373A1 CA 002377373 A CA002377373 A CA 002377373A CA 2377373 A CA2377373 A CA 2377373A CA 2377373 A1 CA2377373 A1 CA 2377373A1
Authority
CA
Canada
Prior art keywords
nitric oxide
neurogenesis
oxide donor
administering
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002377373A
Other languages
French (fr)
Other versions
CA2377373C (en
Inventor
Michael Chopp
Rui Lan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henry Ford Health System
Original Assignee
Henry Ford Health System
Michael Chopp
Rui Lan Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henry Ford Health System, Michael Chopp, Rui Lan Zhang filed Critical Henry Ford Health System
Publication of CA2377373A1 publication Critical patent/CA2377373A1/en
Application granted granted Critical
Publication of CA2377373C publication Critical patent/CA2377373C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/15—Oximes (>C=N—O—); Hydrazines (>N—N<); Hydrazones (>N—N=) ; Imines (C—N=C)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Abstract

There is provided a method of promoting neurogenesis by administering a therapeutic amount of a nitric oxide donor compound to a patient in need of neurogenesis promotion. Also provided is a compound for providing neurogenes is having an effective amount of a nitric oxide donor sufficient to promote neurogenesis. A nitric oxide compound for promoting neurogenesis is also provided. Further, a method of augmenting the production of brain cells and facilitating cellular structural and receptor changes by administering an effective amount of a nitric oxide donor compound to a site in need of augmentation is provided. There is provided a method of increasing both neurological and cognitive function by administering an effective amount of a nitric oxide donor compound to a patient.

Claims (8)

1. A method of promoting neurogenesis comprising the step of:
administering a therapeutic amount of a nitric oxide donor compound to a patient in need of neurogenesis promotion.
2. A compound for promoting neurogenesis comprising an effective amount of a nitric oxide donor sufficient to promote neurogenesis.
3. A neurogenesis promoter comprising a nitric oxide donor in a pharmaceutically acceptable carrier.
4. The neurogenesis promoter according to claim 3, wherein said nitric oxide donor augments nitric oxide in a tissue.
5. The neurogenesis promoter according to claim 4, wherein said nitric oxide donor is selected from the group consisting essentially of phosphodiesterase inhibitors, and L-arginine.
6. A method of augmenting the production of neurons by administering an effective amount of a nitric oxide donor to a site in need of augmentation.
7. A method of increasing neurological function by administering an effective amount of a nitric oxide donor to a patient.
8. A method of increasing cognitive and neurological function by administering an effective amount of a nitric oxide donor compound to a patient.
CA2377373A 1999-06-14 2000-06-14 Nitric oxide donors for inducing neurogenesis Expired - Fee Related CA2377373C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13897199P 1999-06-14 1999-06-14
US60/138,971 1999-06-14
PCT/US2000/016353 WO2000076318A1 (en) 1999-06-14 2000-06-14 Nitric oxide donors for inducing neurogenesis

Publications (2)

Publication Number Publication Date
CA2377373A1 true CA2377373A1 (en) 2000-12-21
CA2377373C CA2377373C (en) 2011-05-10

Family

ID=22484514

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2377373A Expired - Fee Related CA2377373C (en) 1999-06-14 2000-06-14 Nitric oxide donors for inducing neurogenesis

Country Status (14)

Country Link
US (1) US8383626B2 (en)
EP (1) EP1233670B1 (en)
JP (1) JP2003532622A (en)
CN (2) CN1370044A (en)
AT (1) ATE408402T1 (en)
AU (1) AU782283B2 (en)
CA (1) CA2377373C (en)
DE (1) DE60040299D1 (en)
ES (1) ES2313895T3 (en)
HU (1) HUP0202150A3 (en)
IL (1) IL147112A0 (en)
NZ (1) NZ516513A (en)
WO (1) WO2000076318A1 (en)
ZA (1) ZA200110305B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310052B1 (en) 1996-06-04 2001-10-30 Queen's University At Kingston Nitrate esters and their use for neurological conditions
EP1233670B1 (en) 1999-06-14 2008-09-17 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US7135498B1 (en) 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
EP1469852A4 (en) * 2002-01-04 2009-12-02 Ford Henry Health System Nitric oxide donors for treatment of disease and injury
WO2006075642A1 (en) * 2005-01-12 2006-07-20 Ajinomoto Co., Inc. Hypoxia response enhancing agent
JP5274248B2 (en) 2005-05-27 2013-08-28 ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル Nitric oxide releasing particles for nitric oxide therapy and biomedical applications
PL2194781T5 (en) * 2007-10-04 2021-11-15 Société des Produits Nestlé S.A. Compositions and methods for enhancing cognitive function
WO2009088433A1 (en) * 2008-01-04 2009-07-16 Nestec S.A. Compositions comprising unsaturated fatty acids and nitric oxide releasing compounds and use thereof for enhancing congnitive and related functions
BR112012003804B1 (en) 2009-08-21 2019-02-19 Novan, Inc. Wound Dressing, Method to Form an Injury Dressing, and Wound Dressing Kit
EP2467127B1 (en) 2009-08-21 2023-08-02 Novan, Inc. Topical gels
US9023890B2 (en) 2009-12-02 2015-05-05 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
BR112013020802A2 (en) * 2011-02-18 2016-10-04 Nestec Sa methods and compositions for treating, reducing or preventing damage to the nervous system of animals
WO2012118819A2 (en) 2011-02-28 2012-09-07 Novan, Inc. Nitric oxide-releasing s-nitrosothiol-modified silica particles and methods of making the same
US9452117B2 (en) 2011-06-01 2016-09-27 The Charlotte-Mecklenburg Hospital Authority Nitrate esters and their use for the treatment of muscle and muscle related diseases
JP6389125B2 (en) * 2011-11-07 2018-09-12 ザ ジェネラル ホスピタル コーポレイション How to treat red blood cells
PE20142258A1 (en) 2012-04-25 2015-01-15 Takeda Pharmaceutical NITROGENATED HETEROCYCLIC COMPOUND
US9527841B2 (en) 2012-07-13 2016-12-27 Takeda Pharmaceutical Company Limited Substituted pyrido[2,3-b]pyrazines as phosphodiesterase 2A inhibitors
EP2975031A4 (en) 2013-03-14 2017-04-19 Takeda Pharmaceutical Company Limited Heterocyclic compound
WO2015002230A1 (en) 2013-07-03 2015-01-08 武田薬品工業株式会社 Amide compound
US10053468B2 (en) 2013-07-03 2018-08-21 Takeda Pharmaceutical Company Limited Heterocyclic compound
BR112017025664A2 (en) 2015-06-22 2018-08-07 Nestec Sa compositions and methods for enhancing neurogenesis in animals

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4476196A (en) 1983-10-12 1984-10-09 The United States Of America As Represented By The United States Department Of Energy Solid oxide fuel cell having monolithic cross flow core and manifolding
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4959217A (en) 1986-05-22 1990-09-25 Syntex (U.S.A.) Inc. Delayed/sustained release of macromolecules
US4925678A (en) 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5167616A (en) 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5226182A (en) 1992-02-04 1993-07-13 Marilyn Tucker Excrement collection and disposal device and method
US5385940A (en) * 1992-11-05 1995-01-31 The General Hospital Corporation Treatment of stroke with nitric-oxide releasing compounds
US5428070A (en) 1993-06-11 1995-06-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity
EP0721464A4 (en) 1993-09-01 1998-12-30 Start Technology Partnership Neuron regulatory factor for promoting neuron survival
ES2149338T3 (en) * 1993-11-02 2000-11-01 Us Health USE OF COMPOUNDS THAT RELEASE NITRIC OXIDE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT INTENDED FOR THE TREATMENT OF INJURIES BY ISCHEMIC REPERFUSION.
GB9801398D0 (en) * 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
US6423751B1 (en) 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
EP1233670B1 (en) 1999-06-14 2008-09-17 Henry Ford Health System Nitric oxide donors for inducing neurogenesis

Also Published As

Publication number Publication date
ATE408402T1 (en) 2008-10-15
CN101310772A (en) 2008-11-26
ES2313895T3 (en) 2009-03-16
WO2000076318A1 (en) 2000-12-21
EP1233670B1 (en) 2008-09-17
HUP0202150A3 (en) 2003-10-28
AU5488200A (en) 2001-01-02
CN101310772B (en) 2012-02-08
EP1233670A1 (en) 2002-08-28
JP2003532622A (en) 2003-11-05
CN1370044A (en) 2002-09-18
CA2377373C (en) 2011-05-10
AU782283B2 (en) 2005-07-14
ZA200110305B (en) 2002-11-27
DE60040299D1 (en) 2008-10-30
IL147112A0 (en) 2002-08-14
EP1233670A4 (en) 2004-04-14
NZ516513A (en) 2004-03-26
US20110071168A1 (en) 2011-03-24
HUP0202150A2 (en) 2002-10-28
US8383626B2 (en) 2013-02-26

Similar Documents

Publication Publication Date Title
CA2377373A1 (en) Nitric oxide donors for inducing neurogenesis
WO2003000343A3 (en) Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
AU2005202257C1 (en) Azacyclic compounds for use in the treatment of serotonin related diseases
WO2002041883A3 (en) As-needed administration of tricyclic and other non-sri antidepressant drugs to treat premature ejaculation
UA66825C2 (en) Azapolycyclic compounds condensed with aryl
WO2001039762A3 (en) Use of taurolidine or taurultam for the manufacture of a medicament for the treatment of tumors of the central nervous system
EA200001043A2 (en) I:npy inhibitor for treating female sexual dysfunction
GEP20043303B (en) Polycycloalkylpurines as Adenosine Receptor Antagonists
MXPA02002895A (en) Topical treatment of streptococcal infections.
CA2388939A1 (en) Therapeutic treatments for blood cell deficiencies
CA2471147A1 (en) Nitric oxide donors for treatment of disease and injury
HK1059738A1 (en) Methods and pharmaceutical compositions for healing wounds
WO2002026245A3 (en) Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
ATE161725T1 (en) USE OF PHOSPHATE DIESTERS TO TREAT RETINA DISEASES
CA2225788A1 (en) Therapeutic agents and autoimmune diseases
WO2000071520A3 (en) Aryl substituted alkylamines capable of activating nicotinic cholinergic receptors
WO1998006265A3 (en) Treatment of fungal infections using a combination of an anti-fungal compound and an n-alkyl-heterocyclic compound, especially n-dodecyl-morpholine
MD1744F2 (en) Clavulanates and process for preparation thereof
SE9903611D0 (en) Novel compounds III
CA2473749A1 (en) Pure populations of astrocyte restricted precursor cells and methods for isolation and use thereof
WO2003072019A3 (en) Sequential therapy comprising a 20(s)-camptothecin compound and a pyrimidine base analog
WO2001007029A3 (en) Substituted guanidines and the use thereof
IL124128A (en) Composition comprising a benzoylphenylurea for treatment of topical fungal infection
TR199900013T2 (en) New bracelets.
AU2002236587A1 (en) Compositions for adhesion prevention

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160614